| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD38 | Synonyms | ADPRC 1, ADPRC1, cADPR1 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4p15.32 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | CD38 molecule | ||||
| GTO ID | GTC2030 |
| Trial ID | NCT03767751 |
| Disease | Multiple Myeloma |
| Altered gene | CD38|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD38 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma |
| Year | 2018 |
| Country | China |
| Company sponsor | Chinese PLA General Hospital |
| Other ID(s) | CHN-PLAGH-BT-037 |
| Cohort 1 | |||||||
|
|||||||